Browse by category

Key factors that can impact long-term weight loss in patients with obesity prescribed GLP-1 RA medications

Weight reduction at one year is associated with the injectable semaglutide or liraglutide’s active agent, its dosage, treatment...

Semaglutide cardiovascular benefits are maintained in people with impaired kidney function

Semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults...

Semaglutide hydrogel could reduce diabetes shots to once a month

French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and weight control...

No increased risk of mental health issues among those using semaglutide for weight loss

Taking the weight loss medication semaglutide does not increase the risk of depressive symptoms, suicidal thoughts or suicidal behaviour...

Semaglutide reduces COVID-19 related deaths in patients with obesity and CVD

Semaglutide reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established...

Semaglutide’s cardiac benefits extend to people with heart failure

The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events (MACE) among people...

Diabetes severity using the IMS score can predict semaglutide induced weight loss

Diabetes severity, as assessed by the individualised metabolic surgery (IMS), can help predict the weight loss outcomes achieved by...

Journal Watch 10/7/2024

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Patients receiving tirzepatide were significantly more likely to achieve clinically meaningful weight loss compared with those treated receiving semaglutide

Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight...

Semaglutide linked to uncommon blindness condition NAION

Patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of having a potentially blinding eye...

3 4 5

Ratioing the resected gastric volume to the number of fired staplers predicts weight loss

3 days ago

Arrowhead initiates phase 1/2a study of ARO-INHBE for obesity

4 days ago

Survey finds 93.4% of bariatric patients vs 51.4% of GLP-1 patients have the same treatment again

7 days ago

Browse by category

Browse by tag

Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Get in touch!
Email: info@bariatricnews.net